Saltar al contenido
MilliporeSigma

Cardiomyocytes stimulate angiogenesis after ischemic injury in a ZEB2-dependent manner.

Nature communications (2021-01-06)
Monika M Gladka, Arwa Kohela, Bas Molenaar, Danielle Versteeg, Lieneke Kooijman, Jantine Monshouwer-Kloots, Veerle Kremer, Harmjan R Vos, Manon M H Huibers, Jody J Haigh, Danny Huylebroeck, Reinier A Boon, Mauro Giacca, Eva van Rooij
RESUMEN

The disruption in blood supply due to myocardial infarction is a critical determinant for infarct size and subsequent deterioration in function. The identification of factors that enhance cardiac repair by the restoration of the vascular network is, therefore, of great significance. Here, we show that the transcription factor Zinc finger E-box-binding homeobox 2 (ZEB2) is increased in stressed cardiomyocytes and induces a cardioprotective cross-talk between cardiomyocytes and endothelial cells to enhance angiogenesis after ischemia. Single-cell sequencing indicates ZEB2 to be enriched in injured cardiomyocytes. Cardiomyocyte-specific deletion of ZEB2 results in impaired cardiac contractility and infarct healing post-myocardial infarction (post-MI), while cardiomyocyte-specific ZEB2 overexpression improves cardiomyocyte survival and cardiac function. We identified Thymosin β4 (TMSB4) and Prothymosin α (PTMA) as main paracrine factors released from cardiomyocytes to stimulate angiogenesis by enhancing endothelial cell migration, and whose regulation is validated in our in vivo models. Therapeutic delivery of ZEB2 to cardiomyocytes in the infarcted heart induces the expression of TMSB4 and PTMA, which enhances angiogenesis and prevents cardiac dysfunction. These findings reveal ZEB2 as a beneficial factor during ischemic injury, which may hold promise for the identification of new therapies.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Roche
cOmplete, Mini, conjunto de inhibidores de proteasas sin EDTA, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Millipore
Microesferas magnéticas anti-FLAG® M2, affinity isolated antibody
Sigma-Aldrich
ANTI-FLAG® M2 monoclonal antibody produced in mouse, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
2- fosfato del ácido L-ascórbico sesquimagnesium salt hydrate, ≥95%
Sigma-Aldrich
Péptido 3X FLAG®, lyophilized powder
Sigma-Aldrich
Albúmina human, Cellastim S, recombinant, expressed in rice, lyophilized powder, suitable for cell culture, low endotoxin, ≥96% (SDS-PAGE)
Sigma-Aldrich
Gelatina from cold water fish skin, 40-50% in H2O
Sigma-Aldrich
Anticuerpo anti-gliceraldehído-3-fosfato deshidrogenasa, clon 6C5, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
Sodium DL-lactate solution, BioReagent, syrup, 60 % (w/w), synthetic, suitable for cell culture
Sigma-Aldrich
Lectin from Triticum vulgaris (wheat), FITC conjugate, lyophilized powder
Sigma-Aldrich
Anti-α-Actinin (Sarcomeric) antibody, Mouse monoclonal, clone EA-53, purified from hybridoma cell culture
Sigma-Aldrich
Wnt Antagonist II, IWP-2, The Wnt Antagonist II, IWP-2, also referenced under CAS 686770-61-6, controls the biological activity of Wnt. This small molecule/inhibitor is primarily used for Cancer applications.
Sigma-Aldrich
GSK-3 Inhibitor XVI, GSK-3 Inhibitor XVI - CAS 252917-06-9, is a cell-permeable, potent, ATP-competitive, and highly selective GSK-3 inhibitor (IC₅₀ = 10 and 6.7 nM against GSK-3α and GSK-3β, respectively).
Sigma-Aldrich
Anti-ACTN2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution